Sign in

John Evans

Chief Executive Officer at Beam Therapeutics
Board
Since January 2017
Age
46 years
Education
Holds an MBA in Healthcare Management from Wharton, an M.S. in Biotechnology from the University of Pennsylvania, and a B.A. in English with distinction from Yale University.
Tenure
Joined Beam Therapeutics as Chief Executive Officer and board member in January 2017.

Also at Beam Therapeutics

AS
Amy Simon
Chief Medical Officer
CB
Christine Bellon
Chief Legal Officer and Secretary
GC
Giuseppe Ciaramella
President

About

John Evans is a biotechnology executive with a strong track record in driving innovation and leadership within the industry. He has built a career through diverse roles in companies such as Agios Pharmaceuticals, ARCH Venture Partners, and other notable organizations, which provided him with deep expertise in corporate development and portfolio leadership.

He joined Beam Therapeutics in January 2017 as the Chief Executive Officer and a member of the Board, where his strategic guidance has been pivotal in advancing precision genetic medicine.

His academic background from prominent institutions further underpins his professional achievements, while his board memberships at multiple related ventures reflect his broad influence and commitment to the biotechnology sector.

$BEAM Performance Under John Evans

Past Roles

OrganizationRoleDate RangeDetails
ARCH Venture Partners Venture Partner April 2017 - March 2021 N/A
Agios Pharmaceuticals, Inc. Senior Vice President for Corporate Development and Portfolio Leadership September 2009 - April 2017 Early employee and leadership team member
Infinity Pharmaceuticals, Inc. Unknown N/A Worked there prior to Agios
McKinsey & Company Pharmaceuticals Practice Member N/A Participated in the pharmaceuticals practice
MedImmune Unknown N/A Worked at MedImmune

External Roles

OrganizationRoleDate RangeDetails
Orbital Therapeutics, Inc. Board Member N/A Biotechnology company focused on mRNA therapeutics

Fixed Compensation

Data from  FY 2023
Component NameAmountPayment ScheduleAdditional Details
Base Salary$685,000 AnnualIncreased from $650,000 in 2022
Stock Awards$1,722,375 At grant dateRSUs granted computed per FASB ASC 718
Option Awards$3,423,499 At grant dateStock options granted computed per FASB ASC 718
All Other Compensation$17,675 AnnualIncludes sabbatical payments ($5,000), commuting benefits ($1,575), 401(k) matching ($9,900), cell phone allowance ($1,200)
Qualifying Termination Payment$2,362,932 Upon qualifying terminationConsists of Cash Severance ($685,000), Bonus Payment ($411,000), Health Care Continuation ($29,266), Equity Acceleration ($1,237,666)
Change in Control Payment$2,386,024 Upon change in controlIncludes Equity Acceleration of 100% of unvested awards
Change in Control with Qualifying Termination Payment$9,190,154 Upon change in control with qualifying terminationConsists of Cash Severance ($1,027,500), Bonus Payment ($616,500), Health Care Continuation ($43,899), Equity Acceleration ($7,502,256)

Performance Compensation

Data from  FY 2023

Non-Equity Incentive Plan Compensation

MetricDetail
Target Award$411,000 (60% of base salary)
Actual Payment$431,550 (105% of target)
Performance MetricsCorporate performance goals covering Clinical, Research & Development, Manufacturing, Organizational, and Financial objectives
ThresholdsNo threshold specified
Maximum (Cap)No maximum specified
WeightsBonus awarded at 105% of the target based on strong corporate performance
Vesting ScheduleNot applicable (cash bonus)
Evaluation Period2023
Plan DetailsDetermined under the 2019 Cash Incentive Plan; compensation committee and Board holistically assessed goal achievement